Maneka Mirchandaney analyst

Currently out of the existing stock ratings of Maneka Mirchandaney, 10 are a BUY (66.67%), 5 are a HOLD (33.33%).

Maneka Mirchandaney

Work Performance Price Targets & Ratings Chart

Analyst Maneka Mirchandaney, carries an average stock price target met ratio of 63.33% that have a potential upside of 45.43% achieved within 324 days. Previously, Maneka Mirchandaney worked at EVERCORE.

Maneka Mirchandaney’s has documented 31 price targets and ratings displayed on 5 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on CRNX, Crinetics Pharmaceuticals at 15-May-2026.

Wall Street Analyst Maneka Mirchandaney

Analyst best performing recommendations are on SGEN (SEAGEN).
The best stock recommendation documented was for SGEN (SEAGEN) at 5/17/2021. The price target of $153 was fulfilled within 3 days with a profit of $5.02 (3.39%) receiving and performance score of 11.31.

Average potential price target upside

CRNX Crinetics Pharmaceuticals INCY yte INKT Mink Therapeutics SGEN Seagen VRDN Viridian Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 02-Sep-2026

1 months 20 days ago
(02-Sep-2026)

5/8 (62.5%)

$48.39 (116.29%)

407

Buy Since 02-Jul-2026

$85

$0.05 (0.06%)

$55

2 months 24 days ago
(28-Jul-2026)

1/2 (50%)

$1.14 (1.36%)

5

Buy Since 05-Jan-2026

$85

$0.05 (0.06%)

$90

3 months 14 days ago
(08-Jul-2026)

0/2 (0%)

$1.51 (1.81%)

Buy Since 13-Aug-2018

3 months 14 days ago
(08-Jul-2026)

5/5 (100%)

$26.41 (194.33%)

1556

Buy Since 07-Jul-2026

$85

$0.05 (0.06%)

$55

3 months 15 days ago
(07-Jul-2026)

1/2 (50%)

$1.47 (1.76%)

356

Show more analysts

Please expand the browser size to see the chart

Which stock is Maneka Mirchandaney most bullish on?

Potential upside of $6.97 has been obtained for VRDN (VIRIDIAN THERAPEUTICS)

Which stock is Maneka Mirchandaney most reserved on?

Potential downside of $3.05 has been obtained for CRNX (CRINETICS PHARMACEUTICALS)
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?